Phio Pharmaceuticals Ownership 2024 | Who Owns Phio Pharmaceuticals Now?

Overview RevenueFinancials Chart

Institutional Ownership

4.22%

Insider Ownership

1.31%

Retail Ownership

94.48%

Institutional Holders

11.00

Phio Pharmaceuticals Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
RENAISSANCE TECHNOLOGIES LLC	15.08%	0.00%	14,280	14,280	100.00%	80,000	Mar 31, 2023
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC.	15.03%	0.00%	14,233	14,233	100.00%	80,000	Mar 31, 2023
VANGUARD GROUP INC	10.85%	-	10,277	10,277	100.00%	57,757,000	Mar 31, 2023
UBS GROUP AG	0.22%	-	207	207	100.00%	1,163,000	Mar 31, 2023
MORGAN STANLEY	0.13%	-	125	125	100.00%	703,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.01%	-	8	8	100.00%	45,000	Mar 31, 2023
BLACKROCK INC.	0.00%	-	1	1	100.00%	6,000	Mar 31, 2023
TWO SIGMA SECURITIES, LLC	-	-	-	-1,643	-100.00%	-	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-8	-100.00%	-	Mar 31, 2023
GROUP ONE TRADING, L.P.	-	-	-	-42	-100.00%	-	Mar 31, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-1,867	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-1,920	-100.00%	-	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-13,900	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-435	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-8,910	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	-	-	-	-125	-100.00%	-	Mar 31, 2023
VANGUARD GROUP INC	-	-	-	-12,878	-100.00%	-	Mar 31, 2023
CETERA INVESTMENT ADVISERS	-	-	-	-6,250	-100.00%	-	Mar 31, 2023
BLACKROCK INC.	-	-	-	-2	-100.00%	-	Mar 31, 2023

Phio Pharmaceuticals's largest institutional shareholder is RENAISSANCE TECHNOLOGIES LLC, holding 15.08% of the company's total share outstanding, currently valued at $80.00K. The top 10 institutional shareholders own together 41.32% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC.	15.03%	0.00%	14,233	14,233	100.00%	80,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	15.08%	0.00%	14,280	14,280	100.00%	80,000	Mar 31, 2023
VANGUARD GROUP INC	10.85%	-	10,277	10,277	100.00%	57,757,000	Mar 31, 2023
UBS GROUP AG	0.22%	-	207	207	100.00%	1,163,000	Mar 31, 2023
MORGAN STANLEY	0.13%	-	125	125	100.00%	703,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.01%	-	8	8	100.00%	45,000	Mar 31, 2023
BLACKROCK INC.	0.00%	-	1	1	100.00%	6,000	Mar 31, 2023
TWO SIGMA SECURITIES, LLC	-	-	-	-1,643	-100.00%	-	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-8	-100.00%	-	Mar 31, 2023
GROUP ONE TRADING, L.P.	-	-	-	-42	-100.00%	-	Mar 31, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-1,867	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-1,920	-100.00%	-	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-13,900	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-435	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-8,910	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	-	-	-	-125	-100.00%	-	Mar 31, 2023
VANGUARD GROUP INC	-	-	-	-12,878	-100.00%	-	Mar 31, 2023
CETERA INVESTMENT ADVISERS	-	-	-	-6,250	-100.00%	-	Mar 31, 2023
BLACKROCK INC.	-	-	-	-2	-100.00%	-	Mar 31, 2023

The largest Phio Pharmaceuticals shareholder by % of total assets is CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC.. The company owns 14.23K shares of Phio Pharmaceuticals (PHIO), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
RENAISSANCE TECHNOLOGIES LLC	15.08%	0.00%	14,280	14,280	100.00%	80,000	Mar 31, 2023
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC.	15.03%	0.00%	14,233	14,233	100.00%	80,000	Mar 31, 2023
VANGUARD GROUP INC	10.85%	-	10,277	10,277	100.00%	57,757,000	Mar 31, 2023
UBS GROUP AG	0.22%	-	207	207	100.00%	1,163,000	Mar 31, 2023
MORGAN STANLEY	0.13%	-	125	125	100.00%	703,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.01%	-	8	8	100.00%	45,000	Mar 31, 2023
BLACKROCK INC.	0.00%	-	1	1	100.00%	6,000	Mar 31, 2023
BLACKROCK INC.	-	-	-	-2	-100.00%	-	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-8	-100.00%	-	Mar 31, 2023
GROUP ONE TRADING, L.P.	-	-	-	-42	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	-	-	-	-125	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-435	-100.00%	-	Mar 31, 2023
TWO SIGMA SECURITIES, LLC	-	-	-	-1,643	-100.00%	-	Mar 31, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-1,867	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-1,920	-100.00%	-	Mar 31, 2023
CETERA INVESTMENT ADVISERS	-	-	-	-6,250	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-8,910	-100.00%	-	Mar 31, 2023
VANGUARD GROUP INC	-	-	-	-12,878	-100.00%	-	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-13,900	-100.00%	-	Mar 31, 2023

As of Mar 31 2023, Phio Pharmaceuticals's largest institutional buyer is RENAISSANCE TECHNOLOGIES LLC. The company purchased 14.28K stocks of PHIO, valued at $80.00K.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-13,900	-100.00%	-	Mar 31, 2023
VANGUARD GROUP INC	-	-	-	-12,878	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-8,910	-100.00%	-	Mar 31, 2023
CETERA INVESTMENT ADVISERS	-	-	-	-6,250	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-1,920	-100.00%	-	Mar 31, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-1,867	-100.00%	-	Mar 31, 2023
TWO SIGMA SECURITIES, LLC	-	-	-	-1,643	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-435	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	-	-	-	-125	-100.00%	-	Mar 31, 2023
GROUP ONE TRADING, L.P.	-	-	-	-42	-100.00%	-	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-8	-100.00%	-	Mar 31, 2023
BLACKROCK INC.	-	-	-	-2	-100.00%	-	Mar 31, 2023
BLACKROCK INC.	0.00%	-	1	1	100.00%	6,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.01%	-	8	8	100.00%	45,000	Mar 31, 2023
MORGAN STANLEY	0.13%	-	125	125	100.00%	703,000	Mar 31, 2023
UBS GROUP AG	0.22%	-	207	207	100.00%	1,163,000	Mar 31, 2023
VANGUARD GROUP INC	10.85%	-	10,277	10,277	100.00%	57,757,000	Mar 31, 2023
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC.	15.03%	0.00%	14,233	14,233	100.00%	80,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	15.08%	0.00%	14,280	14,280	100.00%	80,000	Mar 31, 2023

As of Mar 31 2023, Phio Pharmaceuticals's biggest institutional seller is RENAISSANCE TECHNOLOGIES LLC. The company sold -13.90K shares of PHIO, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
RENAISSANCE TECHNOLOGIES LLC	15.08%	0.00%	14,280	14,280	100.00%	80,000	Mar 31, 2023
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC.	15.03%	0.00%	14,233	14,233	100.00%	80,000	Mar 31, 2023
VANGUARD GROUP INC	10.85%	-	10,277	10,277	100.00%	57,757,000	Mar 31, 2023
UBS GROUP AG	0.22%	-	207	207	100.00%	1,163,000	Mar 31, 2023
MORGAN STANLEY	0.13%	-	125	125	100.00%	703,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.01%	-	8	8	100.00%	45,000	Mar 31, 2023
BLACKROCK INC.	0.00%	-	1	1	100.00%	6,000	Mar 31, 2023

Phio Pharmaceuticals's largest new institutional shareholder by number of shares is RENAISSANCE TECHNOLOGIES LLC, purchased 14.28K shares, valued at $80.00K, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
RENAISSANCE TECHNOLOGIES LLC	-	-	-	-13,900	-100.00%	-	Mar 31, 2023
VANGUARD GROUP INC	-	-	-	-12,878	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	-	-	-	-8,910	-100.00%	-	Mar 31, 2023
CETERA INVESTMENT ADVISERS	-	-	-	-6,250	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-1,920	-100.00%	-	Mar 31, 2023
TWO SIGMA INVESTMENTS, LP	-	-	-	-1,867	-100.00%	-	Mar 31, 2023
TWO SIGMA SECURITIES, LLC	-	-	-	-1,643	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	-	-	-	-435	-100.00%	-	Mar 31, 2023
MORGAN STANLEY	-	-	-	-125	-100.00%	-	Mar 31, 2023
GROUP ONE TRADING, L.P.	-	-	-	-42	-100.00%	-	Mar 31, 2023
WELLS FARGO & COMPANY/MN	-	-	-	-8	-100.00%	-	Mar 31, 2023
BLACKROCK INC.	-	-	-	-2	-100.00%	-	Mar 31, 2023

Phio Pharmaceuticals's largest sold out institutional shareholder by shares sold is RENAISSANCE TECHNOLOGIES LLC, sold -13.90K shares, valued at -, as of undefined.

Phio Pharmaceuticals Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
BRIDGEWAY FUNDS INC	0.01%	23,486	-	-	Mar 28, 2024
FIDELITY CONCORD STREET TRUST	0.00%	106,258	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	154,536	-	-	Mar 31, 2024
VANGUARD INDEX FUNDS	0.00%	24,380	-24,380	-50.00%	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	9,718	-	-	Feb 29, 2024
DFA INVESTMENT DIMENSIONS GROUP INC	0.00%	29,208	-	-	Jan 31, 2024
EQ ADVISORS TRUST	0.00%	3,001	-	-	Mar 31, 2024
Blackstone Alternative Investment Funds	0.00%	100	-	-	Mar 31, 2023
Blackstone Alternative Investment Funds	0.00%	41	-	-	Mar 31, 2024

Phio Pharmaceuticals's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 23.49K shares, compromising 0.01% of its total assets.

Phio Pharmaceuticals Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Dec, 22	11	-15.38%
30 Sep, 22	13	30.00%
30 Jun, 22	10	-23.08%
31 Mar, 22	13	-27.78%
31 Dec, 21	18	-
30 Sep, 21	18	-10.00%
30 Jun, 21	20	25.00%
31 Mar, 21	16	77.78%
31 Dec, 20	9	28.57%
30 Sep, 20	7	40.00%
30 Jun, 20	5	-16.67%
31 Mar, 20	6	-

As of 31 Dec 22, 11 institutions are holding Phio Pharmaceuticals's shares, representing a decrease of -15.38% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Dec, 22	575,219	-20.85%
30 Sep, 22	726,716	-6.72%
30 Jun, 22	779,036	10.17%
31 Mar, 22	707,147	-28.55%
31 Dec, 21	989,680	10.10%
30 Sep, 21	898,876	28.35%
30 Jun, 21	700,357	45.06%
31 Mar, 21	482,810	57.03%
31 Dec, 20	307,468	200.94%
30 Sep, 20	102,169	-21.70%
30 Jun, 20	130,477	-62.01%
31 Mar, 20	343,483	-

Phio Pharmaceuticals (PHIO) has 575.22K shares outstanding as of 31 Dec 22, down -20.85% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Dec, 22	4.22%	14.91%
30 Sep, 22	5.32%	16.35%
30 Jun, 22	5.70%	20.98%
31 Mar, 22	5.21%	9.75%
31 Dec, 21	7.31%	16.58%
30 Sep, 21	6.64%	24.80%
30 Jun, 21	5.17%	25.32%
31 Mar, 21	4.52%	15.98%
31 Dec, 20	5.32%	170.26%
30 Sep, 20	1.77%	25.60%
30 Jun, 20	2.63%	5.49%
31 Mar, 20	6.92%	-

As of 31 Dec 22, Phio Pharmaceuticals is held by 4.22% institutional shareholders, representing a 14.91% growth compared to 30 Sep 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Dec, 22	3	-57.14%
30 Sep, 22	7	133.33%
30 Jun, 22	3	-57.14%
31 Mar, 22	7	-30.00%
31 Dec, 21	10	11.11%
30 Sep, 21	9	-30.77%
30 Jun, 21	13	8.33%
31 Mar, 21	12	33.33%
31 Dec, 20	9	125.00%
30 Sep, 20	4	-
30 Jun, 20	4	-33.33%
31 Mar, 20	6	-

3 institutional shareholders have increased their position in PHIO stock as of 31 Dec 22 compared to 7 in the previous quarter (a -57.14% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Dec, 22	7	75.00%
30 Sep, 22	4	-33.33%
30 Jun, 22	6	20.00%
31 Mar, 22	5	66.67%
31 Dec, 21	3	-40.00%
30 Sep, 21	5	150.00%
30 Jun, 21	2	100.00%
31 Mar, 21	1	-
31 Dec, 20	-	-100.00%
30 Sep, 20	3	200.00%
30 Jun, 20	1	-
31 Mar, 20	-	-

7 institutional shareholders have reduced their position in PHIO stock as of 31 Dec 22 compared to 4 in the previous quarter (a 75.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Dec, 22	11	-15.38%	575,219	-20.85%	4.22%	14.91%	3	-57.14%	7	75.00%
30 Sep, 22	13	30.00%	726,716	-6.72%	5.32%	16.35%	7	133.33%	4	-33.33%
30 Jun, 22	10	-23.08%	779,036	10.17%	5.70%	20.98%	3	-57.14%	6	20.00%
31 Mar, 22	13	-27.78%	707,147	-28.55%	5.21%	9.75%	7	-30.00%	5	66.67%
31 Dec, 21	18	-	989,680	10.10%	7.31%	16.58%	10	11.11%	3	-40.00%
30 Sep, 21	18	-10.00%	898,876	28.35%	6.64%	24.80%	9	-30.77%	5	150.00%
30 Jun, 21	20	25.00%	700,357	45.06%	5.17%	25.32%	13	8.33%	2	100.00%
31 Mar, 21	16	77.78%	482,810	57.03%	4.52%	15.98%	12	33.33%	1	-
31 Dec, 20	9	28.57%	307,468	200.94%	5.32%	170.26%	9	125.00%	-	-100.00%
30 Sep, 20	7	40.00%	102,169	-21.70%	1.77%	25.60%	4	-	3	200.00%
30 Jun, 20	5	-16.67%	130,477	-62.01%	2.63%	5.49%	4	-33.33%	1	-
31 Mar, 20	6	-	343,483	-	6.92%	-	6	-	-	-

Phio Pharmaceuticals Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 11, 2024	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	1,000	$0.74	$740.00	20,990
Jun 10, 2024	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	1,000	$0.75	$750.00	19,990
Feb 27, 2024	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	2,500	$0.91	$2.27K	18,990
Jul 05, 2023	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	1,000	$2.84	$2.84K	19,211
Jul 05, 2023	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	1,000	$2.88	$2.88K	18,211
Jun 15, 2023	Ferrara Robert L	director	-	P-Purchase	Buy	2,000	$3.10	$6.20K	6,000

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 11, 2024	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	1,000	$0.74	$740.00	20,990
Jun 10, 2024	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	1,000	$0.75	$750.00	19,990
Feb 27, 2024	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	2,500	$0.91	$2.27K	18,990
Jul 05, 2023	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	1,000	$2.84	$2.84K	19,211
Jul 05, 2023	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	1,000	$2.88	$2.88K	18,211
Jun 15, 2023	Ferrara Robert L	director	-	P-Purchase	Buy	2,000	$3.10	$6.20K	6,000

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Mar 05, 2024	Kontulis Caitlin	officer	Secretary & VP Finance & Admin	F-InKind	Sell	335	$0.96	$320.93	10,643
Feb 22, 2024	Bitterman Robert J	director, officer	President & CEO	F-InKind	Sell	1,804	$0.76	$1.37K	16,490
Feb 20, 2024	Kontulis Caitlin	officer	Secretary & VP Finance & Admin	F-InKind	Sell	658	$0.65	$427.70	11,501
Feb 20, 2024	Kontulis Caitlin	officer	Secretary & VP Finance & Admin	F-InKind	Sell	523	$0.66	$345.18	10,978
Oct 03, 2023	Bitterman Robert J	director, officer	President & CEO	F-InKind	Sell	917	$1.51	$1.38K	18,294
Mar 03, 2023	Kontulis Caitlin	officer	Secretary & VP Finance & Admin	F-InKind	Sell	335	$5.49	$1.84K	12,159

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Aug 15, 2024	Infarinato Robert M.	officer	VP, Chief Financial Officer	A-Award	Buy	8,000	-	-	8,000
Aug 09, 2024	Infarinato Robert M.	officer	-		Buy	-	-	-	-
Jun 11, 2024	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	1,000	$0.74	$740.00	20,990
Jun 10, 2024	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	1,000	$0.75	$750.00	19,990
Mar 05, 2024	Kontulis Caitlin	officer	Secretary & VP Finance & Admin	F-InKind	Sell	335	$0.96	$320.93	10,643
Feb 27, 2024	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	2,500	$0.91	$2.27K	18,990
Feb 22, 2024	Bitterman Robert J	director, officer	President & CEO	F-InKind	Sell	1,804	$0.76	$1.37K	16,490
Feb 20, 2024	Kontulis Caitlin	officer	Secretary & VP Finance & Admin	F-InKind	Sell	658	$0.65	$427.70	11,501
Feb 20, 2024	Kontulis Caitlin	officer	Secretary & VP Finance & Admin	F-InKind	Sell	523	$0.66	$345.18	10,978
Oct 03, 2023	Bitterman Robert J	director, officer	President & CEO	F-InKind	Sell	917	$1.51	$1.38K	18,294
Jul 05, 2023	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	1,000	$2.84	$2.84K	19,211
Jul 05, 2023	Bitterman Robert J	director, officer	President & CEO	P-Purchase	Buy	1,000	$2.88	$2.88K	18,211
Jun 15, 2023	Ferrara Robert L	director	-	P-Purchase	Buy	2,000	$3.10	$6.20K	6,000
Mar 03, 2023	Kontulis Caitlin	officer	Secretary & VP Finance & Admin	F-InKind	Sell	335	$5.49	$1.84K	12,159
Feb 22, 2023	Lockshin Curtis	director	-	A-Award	Buy	1,500	-	-	3,197
Feb 22, 2023	Freeman Jonathan E	director	-	A-Award	Buy	1,500	-	-	3,197
Feb 22, 2023	Ferrara Robert L	director	-	A-Award	Buy	1,500	-	-	4,000
Feb 22, 2023	CAUWENBERGH GEERT	director	-	A-Award	Buy	1,500	-	-	4,235
Feb 22, 2023	BRADFORD PATRICIA A	director	-	A-Award	Buy	1,500	-	-	3,167
Feb 22, 2023	Kontulis Caitlin	officer	Secretary & VP Finance & Admin	A-Award	Buy	4,500	-	-	12,494

The last insider sell of Phio Pharmaceuticals's stock was made by Kontulis Caitlin on Mar 05 2024, selling 335 shares at $0.96 per share (valued at $320.93). The last insider buy of PHIO was made by Bitterman Robert J on Jun 11 2024, buying 1,000 shares at $0.74 per share (worth $740.00).

Phio Pharmaceuticals Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	1	-	-
Q2 2024	2	-	-
Q1 2024	1	4	25.00%
Q4 2023	-	1	-
Q3 2023	1	-	-
Q2 2023	2	-	-
Q1 2023	7	2	350.00%
Q4 2022	9	-	-
Q3 2022	1	-	-
Q2 2022	-	-	-
Q1 2022	8	2	400.00%
Q3 2021	1	-	-
Q1 2021	11	-	-
Q3 2020	1	-	-
Q1 2020	-	1	-
Q4 2019	5	-	-
Q3 2019	-	3	-
Q2 2019	1	-	-
Q1 2019	13	-	-
Q4 2018	6	-	-

1 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Phio Pharmaceuticals's insiders, as of Q3 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q3 2024	-	-	-
Q2 2024	2	-	-
Q1 2024	1	-	-
Q4 2023	-	-	-
Q3 2023	1	-	-
Q2 2023	2	-	-
Q1 2023	-	-	-
Q4 2022	8	-	-
Q3 2022	-	-	-
Q2 2022	-	-	-
Q1 2022	-	-	-
Q3 2021	1	-	-
Q1 2021	3	-	-
Q3 2020	1	-	-
Q1 2020	-	-	-
Q4 2019	-	-	-
Q3 2019	-	-	-
Q2 2019	-	-	-
Q1 2019	-	-	-
Q4 2018	-	-	-

As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Phio Pharmaceuticals's stocks.

Phio Pharmaceuticals Peer Ownership

Ticker	Company
ZVSA	ZyVersa Therapeutics, Inc.
CNSP	CNS Pharmaceuticals, Inc.
CWBR	CohBar, Inc.
VECT	VectivBio Holding AG
AVRO	AVROBIO, Inc.
EFTR	eFFECTOR Therapeutics, Inc.
IMMX	Immix Biopharma, Inc.
OCEA	Ocean Biomedical, Inc.
SONN	Sonnet BioTherapeutics Holdings, Inc.
ZURA	Zura Bio Limited
ELEV	Elevation Oncology, Inc.
CDIO	Cardio Diagnostics Holdings, Inc.
ATNF	180 Life Sciences Corp.

PHIO Ownership FAQ

Who Owns Phio Pharmaceuticals?

Phio Pharmaceuticals is owned by institutional shareholders (4.22%), insiders (1.31%), and public (94.48%). The largest institutional shareholder of Phio Pharmaceuticals is RENAISSANCE TECHNOLOGIES LLC (15.08% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.01% of total shares).

Who are the major institutional shareholders of Phio Pharmaceuticals?

Phio Pharmaceuticals's major institutional shareholders are RENAISSANCE TECHNOLOGIES LLC, CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC., VANGUARD GROUP INC, UBS GROUP AG, and MORGAN STANLEY. The top five shareholders own together 41.31% of the company's share outstanding.

How many Phio Pharmaceuticals shareholders are there?

As of Dec 2022, there are 11 institutional shareholders of Phio Pharmaceuticals.

What percentage of Phio Pharmaceuticals is owned by RENAISSANCE TECHNOLOGIES LLC?

RENAISSANCE TECHNOLOGIES LLC owns 14.28K shares of Phio Pharmaceuticals, representing 15.08% of the company's total shares outstanding, valued at $80K (as of Mar 2023).

What percentage of Phio Pharmaceuticals is owned by CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC?

As of Mar 2023, CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC holds 14.23K shares of Phio Pharmaceuticals (PHIO), compromising 15.03% of the company, valued at $80K.

What percentage of Phio Pharmaceuticals is owned by VANGUARD GROUP INC?

VANGUARD GROUP INC is the third largest holder of Phio Pharmaceuticals. The company owns 10.28K of the company's shares outstanding (worth $57.76M).